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Background Pregnant and postpartum women with severe
hypertension are at increased risk of stroke and require blood
pressure (BP) reduction. Parenteral antihypertensives have been
most commonly studied, but oral agents would be ideal for use in
busy and resource-constrained settings.
Objectives To review systematically, the effectiveness of oral
antihypertensive agents for treatment of severe pregnancy/
postpartum hypertension.
Search strategy A systematic search of MEDLINE, EMBASE and
the Cochrane Library was performed.
Selection criteria Randomised controlled trials in pregnancy and
postpartum with at least one arm consisting of a single oral
antihypertensive agent to treat systolic BP ≥ 160 mmHg and/or
diastolic BP ≥ 110 mmHg.
Data collection and analysis Cochrane REVMAN 5.1 was used to
calculate relative risk (RR) and weighted mean difference by
random effects.
Main results We identified 15 randomised controlled trials (915
women) in pregnancy and one postpartum trial. Most trials in
pregnancy compared oral/sublingual nifedipine capsules
(8–10 mg) with another agent, usually parenteral hydralazine or
labetalol. Nifedipine achieved treatment success in most women,
similar to hydralazine (84% with nifedipine; relative risk [RR]
1.07, 95% confidence interval [95% CI] 0.98–1.17) or labetalol
(100% with nifedipine; RR 1.02, 95% CI 0.95–1.09). Less than 2%
of women treated with nifedipine experienced hypotension. There
were no differences in adverse maternal or fetal outcomes. Target
BP was achieved ~ 50% of the time with oral labetalol (100 mg)
or methyldopa (250 mg) (47% labetelol versus 56% methyldopa;
RR 0.85 95% CI 0.54–1.33).
Conclusions Oral nifedipine, and possibly labetalol and
methyldopa, are suitable options for treatment of severe
hypertension in pregnancy/postpartum.
Keywords Antihypertensive therapy, hypertensive disorders of
pregnancy, oral agents, pregnancy, severe hypertension.
Linked article This article is commented on by Norton ME,
p 1220 in this issue. To view this mini commentary visit http://
dx.doi.org/10.1111/1471-0528.12738. The article has journal club
questions by Duffy JMN, p.1219 in this issue.
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Background
International guidelines define severe pregnancy hyperten-
sion as systolic blood pressure (sBP) ≥ 160–170 mmHg
and/or diastolic BP (dBP) ≥ 110 mmHg.1–3 Severe hyper-
tension is the only modifiable end-organ complication of
pre-eclampsia, the most dangerous of the hypertensive dis-
orders of pregnancy (HDP). However, severe hypertension
may occur in association with any of the HDP, and either
antenatally, intrapartum or postpartum.
It is widely accepted that women with severe hyperten-
sion are at increased risk of stroke and, as such, must have
their BP lowered.4,5 In the latest report from the Centre
for Maternal and Child Enquiries (CMACE) in the UK
(2006–08), failure to treat sustained severe hypertension
was identified as the most common cause of substandard
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Systematic review
care of women with pre-eclampsia who die in the UK;5 12
of the 18 women who died from pre-eclampsia suffered
from severe hypertension-related intracerebral haemorrhage
or cerebral infarction.
All international pregnancy hypertension guidelines
recommend immediate treatment of severe pregnancy
hypertension, a recommendation endorsed as ‘strong’ by
the World Health Organization (WHO).6 While severe
pregnancy hypertension is a ‘hypertensive urgency’ that
requires treatment, it is appropriate to lower BP over hours
(and certainly within 24 hours) and this could be achieved
with oral or parenteral antihypertensive therapy.
Traditionally, severe hypertension has been treated with
short-acting parenteral antihypertensive agents, most
frequently, intravenous hydralazine or labetalol.7–9 These
agents have been most widely studied in randomised con-
trolled trials (RCTs), although systematic reviews have
failed to reveal clear differences between agents.10,11 Paren-
teral agents require more resources than do oral antihyper-
tensive agents, in terms of equipment (i.e. intravenous
tubing, syringes and needles) and personnel (as administra-
tion is by nurses or often, doctors). Also, parenteral agents
require more monitoring and supervision because they are
rapidly-acting and have the potential to lower BP within
minutes and cause maternal hypotension and fetal com-
promise.
Oral therapy would be particularly attractive for commu-
nity or office treatment of severe hypertension (while organ-
ising transport to facility) or in resource-constrained settings.
The objective of this systematic review was to assess the
effectiveness of oral antihypertensive therapy for treatment
of severe pregnancy or postpartum hypertension by review-
ing relevant RCT evidence.
Methods
We undertook a comprehensive search for RCTs of oral
antihypertensives for severe hypertension in pregnancy or
postpartum, with no limitation on year of publication. The
search strategy included the following databases: Medline
using Pubmed, Excerpta Medica Database (Embase), the
Cochrane Central Register of Controlled Trials (CCRCT),
Cochrane Database of Systematic Reviews (CDSR), and
Database of Abstracts of Reviews (DARE) up to 9 July 2012.
In addition, we also searched bibliographies of retrieved
papers and the authors’ personal files. For trials in and out-
side pregnancy, abstracts without accompanying articles
were included if they otherwise met inclusion criteria. Trials
with quasi-randomisation were excluded.
The complete search strategy is summarised in Table 1.
In brief, to identify RCTs, the search terms used were:
‘antihypertensive agents’, ‘oral or sublingual’, ‘hyperten-
sion’, ‘hypertensive urgency’, ‘hypertensive emergency’,
‘hypertensive encephalopathy’ and ‘randomised controlled
trials’. The search was limited to ‘pregnancy, postpartum
and puerperium’. Criteria for inclusion were severe hyper-
tension (defined as a sBP ≥ 160 mmHg, dBP ≥ 110 mmHg,
and/or mean arterial BP ≥ 127, either as inclusion criteria
or as mean BP at enrolment), use of oral or sublingual
antihypertensive therapy in at least one of the treatment
arms, and at least one relevant measure of effectiveness
within 24 hours of drug administration, as all guidelines
state that BP must be lowered within that time frame.
All HDP were included and there were no language
restrictions. Outcomes were adapted from published sys-
tematic reviews: the Cochrane Pregnancy & Childbirth
Group for trials in pregnancy/postpartum, and the Brazil-
ian Cochrane Centre for treatment of hypertensive urgen-
cies (see Table S1).10 We defined the postpartum period as
up to 42 days after delivery. Maternal outcomes in preg-
nancy and postpartum included: caesarean delivery, placen-
tal abruption and maternal end-organ complications closely
associated with pre-eclampsia (e.g. eclampsia). Perinatal
outcomes included adverse effects on fetal heart rate, still-
birth, Apgar scores at 1 and 5 minutes, neonatal death and
admission to a neonatal intensive care unit. Outcomes defi-
nitions were documented at data abstraction and consid-
ered as potential sources of between-study variation in
outcomes. For duplicate publications, the most complete
data set was used for any given outcome.
The quality of each trial was evaluated independently by
two reviewers using the Cochrane Risk of Bias assessment
tool (Table 2). Data were abstracted independently by two
reviewers (LAM and TF) and discrepancies were resolved by
discussion. The included trials were presented descriptively,
and then the COCHRANE REVIEW MANAGER 5.1 was used for
statistical analysis. Data were entered by subgroup according
to the type of antihypertensive in each arm. We determined
heterogeneity between studies by: examining the forest plot
(of relative risk [RR] for each trial) and using the I2 statistic.
When heterogeneity between trials was found, we sought to
explain it by examining differences in study design, women
enrolled, intervention administered and/or outcomes defini-
tions. The summary statistic was RR (and 95% confidence
interval [95% CI]) by random effects model. For continuous
variables, the weighted mean difference and 95% CI were
used (random effects model). In addition, we calculated risk
difference (RD), a measure of absolute effect that is both
sensitive to between-trial differences in absolute event rates
and inclusive of data from all trials, even those without
reported events in either treatment arm.
The manuscript was prepared in accordance with the
PRISMA checklist.11 A protocol of the systematic review
was not published.
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Results
Pregnancy and postpartum
Of 465 papers identified, 16 published from 1982 to 2011
met eligibility criteria: 15 in pregnancy12–29 (914 women)
(one of which was a three-armed trial)26 and one a post-
partum trial (38 women)24 (Figure 1). Two abstracts were
later published as full studies.28,29 The reasons for exclu-
sion were: no randomisation,30,31 enrolment of women
with nonsevere hypertension,32 failure to identify one
Table 1. Search strategy
Medline Embase CDRT
Antihypertensive
medications
Antihypertensive agents OR
calcium channel blockers
Exp antihypertensive
agent/OR exp calcium
channel blocking agent/
Oral or sublingual
therapy
Oral* or sublingual* or sub-lingual* Exp oral drug administration/
OR exp sublingual drug
administration/OR (oral* or
sublingual* or sub-lingual*).mp.
OR li.fs. OR po.fs
Hypertensive disorder Hypertensive Encephalopathy[mh]
OR hypertension/complications[mh]
OR hypertens* urgenc* OR hypertens*
emerg* OR Hypertensive Encephalopathy
OR (severe and hypertension) OR
(hypertensive and crisis) OR (acute and
hypertens*) OR (acute and treatment and
hypertension) OR (acute and blood and
pressure and lowering and effect) OR
(malignant and hypertension) OR
(accelerat* and hypertension) OR
(hypertensive and encephalopat*)
Exp hypertensive crisis/OR
(hypertension cris* OR hypertens*
urgenc* OR hypertens* emerg*
OR Hypertens* Encephalopat*
OR severe hypertens* OR acute
hypertens* OR malignant
hypertens* OR accelerat*
hypertens*).mp.
Hypertension cris* or hypertens*
urgenc* or hypertens* emerg*
or Hypertens* Encephalopat*
or severe hypertens* or acute
hypertens* or malignant
hypertens* or accelerat*
hypertens*
Randomised
controlled trials
Controlled trial [pt] OR controlled clinical
trial [pt] OR clinical trial [pt] OR
randomized controlled trials [mh] OR
random allocation [mh] OR double-blind
method [mh] OR single-blind method [mh]
OR (“clinical trial” [tw]) OR ((single*[tw] OR
doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND
(mask*[tw] OR blind*[tw])) OR placebos[tw]
OR randomi*[tw] OR research
design[mh:noexp] OR comparative
study[pt] OR Evaluation Studies[PT]
OR Evaluation Studies as Topic[mh]
OR follow-up studies[mh] OR prospective
studies[mh] OR control[tw] OR control[tw]
OR controls[tw] OR controll* OR
prospective*[tw] OR volunteer*[tw]
Exp “randomized controlled
trial (topic)”/OR exp randomization/
OR double blind procedure/OR single
blind procedure/OR clinical trial/OR
(single mask* OR doubl* mask* OR
trebl* mask* or tripl* mask* or singl*
blind* OR doubl* blind* or trebl*
blind* or tripl* blind*).mp. OR
(placebo* or randomi*).mp. OR
exp evaluation/OR exp follow up/
OR exp prospective study/OR
(control* or prospective* OR
volunteer*).mp. OR exp comparative
study/OR Applied Limits: [clinical trial or
randomized controlled trial or
controlled clinical trial])
Pregnancy (additional
terms for trials in
pregnancy and
postpartum)
Pregnancy [mh] OR Pregnan* OR
Gestation* OR pregnant women[mh]
OR Pregnancy
Complications[mh] OR “Postpartum
Period”[Mesh] OR Puerperium OR
postpartum OR “Peripartum
Period”[Mesh] OR Peripartum* OR
Perinatal Care[mh] OR perinatal
Exp pregnancy/OR Pregnan*.mp. or
Gestation*.mp. OR exp pregnant
woman/OR exp pregnancy
complication/OR exp puerperium/
OR postpartum.mp. OR
Peripartum Period.mp. or exp
perinatal period/OR Peripartum*.mp.
OR exp perinatal care/OR
perinatal.mp. OR exp pregnancy
disorder/
Pregnan* or Gestation* or
puerper* or postpart* or
Peripart* or perinat*
Filter Humans Humans
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antihypertensive treatment arm as administered orally or
parenterally,33 and inability to obtain abstracts for review
(despite contacting our local libraries and the Cochrane
library).34,35
Trials were generally small with a median of 50 women
(range 20–150). There was a wide range of HDP type at
inclusion, most commonly pre-eclampsia deemed to be
severe, of onset at < 34 weeks of gestation, or complicated
by eclampsia (nine trials); fewer trials enrolled women with
any HDP (three trials), gestational hypertension (two trials)
or an unspecified HDP (one trial). Gestational age at enrol-
ment varied, as follows: > 20 weeks (two trials), ≥ 24 weeks
(four trials), > 28 weeks (four trials), < 34 weeks (one trial),
< 36 weeks (two trials), or was not stated (two trials). The
median BP values at enrolment in the intervention and con-
trol arms were 167/109 mmHg versus 169/114 mmHg,
respectively. When specified, the BP treatment goal was
usually a dBP < 110 mmHg (seven trials) or < 100 mmHg
(three trials), to be achieved over a short time frame:
20 minutes,15 90 minutes12 or 120 minutes.13,18,21
The quality of each trial was fair at best (Table 2). An
unclear risk of bias was seen for most trials for sequence
generation (8 out of 15), allocation concealment (9 out of
15) and masking (10 out of 15), and incomplete outcome
data (14 out of 15). An unclear risk of bias was seen for all
trials for selective outcome reporting.
Nifedipine
Twelve RCTs compared oral/sublingual nifedipine capsules
or tablets (5–10 mg, 724 women) with another agent. Most
compared nifedipine with intravenous hydralazine (5–20 mg,
seven trials, 350 women)13,14,16,19–21 or intravenous labetalol
(20 mg, two trials, 100 women).17,23 Other trials compared
short-acting nifedipine with oral nifedipine 10 mg prolonged
action (PA) tablets (one trial),12 oral prazosin 1 mg (one
trial)22 or intravenous/intramuscular chlorpromazine 12.5 mg
(one trial).18 The postpartum RCT (38 women) compared
sublingual nifedipine with intravenous hydralazine.24
Nifedipine was administered as a capsule (eight trials),
tablet (three trials; one was a comparison of capsule versus
tablet), or the formulation was unclear (two trials). Nifedi-
pine was administered by capsule puncture/biting (n = 4),
swallowing of capsule whole (n = 1), or by an unclear
method (n = 3).
Nifedipine capsules (10 mg orally), compared with nifedi-
pine PA tablets (10 mg orally), were associated with more
maternal hypotension (< 110/80 mmHg) at 90 minutes
(35% versus 9%; RD 0.26, 95% CI 0.07–0.46, one trial, 64
women).12 No fetal deaths were reported in either arm. The
absolute rate of hypotension with nifedipine capsules in this
trial (35%) was higher than that seen in the six other nifedi-
pine capsule trials of similar dosage (8–10 mg) where the
rate of maternal hypotension was 3/158 women (absolute
rate 1.90%, RD 0.01, 95% CI – 0.02 to 0.03; six trials).
When short-acting nifedipine was compared with intra-
venous hydralazine in pregnancy, there was no difference
in effectiveness, as seen by: achievement of target BP (84%
[nifedipine] versus 79% [hydralazine]; RR 1.07 95% CI
0.98–1.17; five trials, 273 women), the time taken to
achieve the target BP (weighted mean difference
Table 2. Study quality
Study Sequence
generation
Allocation
concealment
(selection bias)
Blinding Selective
outcome
reporting
Incomplete
outcome data
Pregnancy
Australia 2002 (Brown) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Brazil 1992 (Martins-Costa) Low risk Unclear risk Low risk Unclear risk Unclear risk
Brazil 1994 (Mesquita-Duley) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Iran 2002 (Aali) Unclear risk Low risk Unclear risk Unclear risk Unclear risk
Iran 2011 (Rezaei) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Malaysia 2011 (Raheem) Low risk Unclear risk Unclear risk Unclear risk Unclear risk
Mexico 1989 (Walss-Rodriguez) Low risk Low risk Unclear risk Unclear risk Unclear risk
Mexico 1993 (Walss-Rodriguez) Low risk Low risk Unclear risk Unclear risk Unclear risk
New Zealand 1992 (Duggan) Unclear risk Unclear risk Low risk Unclear risk Unclear risk
South Africa 1989 (Seabe) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
South Africa 2000 (Hall) Low risk Low risk High risk Unclear risk Unclear risk
USA 1999 (Vermillion and Scardo) Low risk Low risk Low risk Unclear risk Unclear risk
England 1982 (Moore) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Argentina 1990a (Voto) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Argentina 1990b (Voto) Unclear risk Unclear risk Unclear risk Unclear risk Unclear risk
Mexico 1998 (Vargas) Unclear risk Unclear Unclear risk Unclear risk Unclear risk
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1.36 hours, 95% CI 6.64 to 4.14), or the need for a
repeat dose(s) of antihypertensive (51% versus 55%; RR
0.97 95% CI 0.50–1.88; four trials, 246 women). Maternal
hypotension was unusual and did not differ between groups
(1.6% versus 0%; RD 0.00 95% CI 0.02 to 0.03; four trials,
246 women) (Figure 2). There were no maternal deaths
reported (RD 0.00 95% CI 0.03 to 0.03; three trials, 96
women). There were no differences in perinatal outcomes
reported (caesarean delivery, adverse fetal heart rate effects,
Apgar score < 7 at 5 minutes, perinatal death, neonatal death
or stillbirth) (see Table S2). One RCT (38 women) compared
sublingual nifedipine with intravenous hydralazine postpar-
tum, with no between-group differences demonstrated in the
need for additional antihypertensive therapy (5% versus
28%; RR 0.18, 95% CI 0.02–1.40; one trial, 38 women).35
When short-acting nifedipine was compared with intra-
venous labetalol (two trials, 100 women), there was no dif-
ference in maternal or perinatal outcomes (see Table S3).
Of particular note, there was no difference in achievement
of successful treatment (RR 1.02, 95% CI 0.95–1.09, two
trials, 100 women).
Nifedipine capsules, compared with oral prazosin, were
associated with fewer Caesarean deliveries (64% versus
70%; RR 0.90, 95% CI 0.07–0.53, 150 women). Although
not statistically significant, there appeared to be fewer still-
births in the nifedipine group (6/75) compared with the
oral prazosin group (13/74).
Labetalol and methyldopa
There was a single trial (74 women) that compared oral labe-
talol 100 four times daily with oral methyldopa 250 mg four
times daily.25 There was no difference in achievement of tar-
get BP (47% versus 56%; RR 0.85 95% CI 0.54–1.33)
although the time over which BP was lowered was not stated.
No between-group differences were seen in caesarean deliv-
ery (50% versus 59%; RR 0.85, 95% CI 0.56–1.30) or perina-
tal death (5% versus 0%; RD 0.05 95% CI  0.03 to 0.14).
A three-arm trial compared oral methyldopa with either
oral atenolol (50–200 mg) or ketanserin (80–120 mg).26 This
trial did not report on effectiveness in lowering BP. Perinatal
outcomes did not differ between the groups (see Table S4).
Other antihypertensive agents
One small trial (36 women) compared sublingual isosor-
bide with parenteral magnesium sulphate and found no
difference between groups in requirements for additional
antihypertensive therapy (0% versus 17%; RR 0.14, 95% CI
0.01–2.58) although there were fewer caesarean deliveries in
the sublingual isosorbide group (16% versus 89%; RR 0.19,
95% CI 0.07–0.53).27
Discussion
Main findings
Based on RCTs in pregnancy and postpartum, we found
that a single oral agent can adequately lower BP when
Figure 1. Literature search results.
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compared with parenteral agents. In particular, oral nifedi-
pine (10 mg), compared with parenteral hydralazine or lab-
etalol, is a suitable oral agent for treatment of severe
hypertension in pregnancy or postpartum, with: similar
and high treatment success rates (of at least 84%); low
rates of maternal hypotension (< 2%, 3/158 women in six
trials comparing nifedipine with either intravenous hydral-
azine or labetalol); and similar maternal and perinatal out-
comes. Although there was one 10-mg nifedipine capsule
versus 10-mg PA tablet trial that did report more hypoten-
sion with the capsule formulation, the absolute rates of
hypotension were high in both arms of this trial (35% in
the capsule arm and 9% in the 10-mg tablet arm) com-
pared with the six other nifedipine capsule trials of similar
dosage (3/158, 1.90%); also, that hypotension was not nec-
essarily associated with adverse clinical effects.
The few, small comparative trials of other antihyper-
tensive agents in pregnancy/postpartum preclude any
firm conclusions. However, the limited data suggest that
oral labetalol and methyldopa may be effective in
approximately 50% of pregnant women. Caution should
be exercised if considering use of oral prazosin given its
association with more caesarean deliveries and, possibly,
stillbirths.
Strengths
We captured a large number of studies of oral antihyper-
tensive treatment of severe hypertension in pregnancy/
postpartum, given our search of multiple sources and no
language restriction. We also defined and presented abso-
lute rates of treatment success.
Weaknesses
The first limitation of our review is that we had a mean-
ingful body of RCTs for the nifedipine versus other antihy-
pertensive (particularly intravenous hydralazine in
pregnancy) comparisons, but all others were underpowered
to find important between-group differences in outcomes
given the limited number and size of trials. Second, our
results are limited by poor to fair study quality.
Interpretation
To our knowledge, this is the first systematic review to spe-
cifically examine oral antihypertensive therapy for severe
Figure 2. Maternal hypotension.
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hypertension in pregnancy and postpartum. There are,
however, other meta-analyses of trials of short-acting par-
enteral agents that include oral nifedipine in pregnancy/
postpartum, and the results of the oral nifedipine versus
parenteral hydralazine subgroup are consistent with our
analysis.9,10
Outside pregnancy, American guidelines recommend
that antihypertensive therapy be initiated with two oral
agents for treatment of severe hypertension. This recom-
mendation is based on the multi-factorial nature of the
BP elevation and the limited (but variable) average BP
reduction of 9.1 mmHg in sBP and 5.5 mmHg in dBP
achieved after treatment with any one agent.36 In preg-
nancy, initiating antihypertensive therapy with a single
agent may be more appropriate given the intravascular
volume depletion associated with both severe hypertension
and pre-eclampsia,37 and the potential for fetal compro-
mise if BP is lowered too quickly. In the regional
pre-eclampsia guidelines from Yorkshire, UK, labetalol
200 mg is administered orally before intravenous access is
secured, with a repeat dose given if no response is seen
after 30 minutes.38 The 2010 UK National Institute for
Health and Clinical Excellence (NICE) Hypertension in
Pregnancy guideline recommends oral labetalol or nifedi-
pine for the treatment of severe hypertension in women
during pregnancy or after birth.2
Our review presents reasonable options for oral anti-
hypertensive therapy of severe hypertension in pregnancy
or postpartum. First, options are key as there may be
contraindications to use of a given drug (or women may
already be on high doses of an oral agent when they
present with severe hypertension). For example, there are
published concerns about heightened cardiovascular
morbidity/mortality associated with use of short-acting
nifedipine outside pregnancy,39,40 and neuromuscular
blockade with contemporaneous use of magnesium sul-
phate and nifepidine in pregnancy (although the risk was
estimated to be < 1% in a controlled study that incorpo-
rated data from RCTs).41 The usefulness of beta-blockers
may be limited in areas where reactive airways disease is
prevalent and air quality is poor (such as in Pakistan).42–
44 Second, options for oral antihypertensive therapy are
available; the 2012 Priority Medicines for Mothers and
Children, a list of essential life-saving medications for
women and children, has included methyldopa and
hydralazine as antihypertensive agents, and nifedipine is
also listed (albeit as a tocolytic).45 All of these medica-
tions are on the essential medicines lists of most low-
and middle-income countries.46 Finally, based on proven
effectiveness for treatment of severe hypertension outside
pregnancy, there may be other treatment options that
have not been studied in pregnancy or particularly, post-
partum. For example, captopril is acceptable for use dur-
ing breastfeeding and is known to be an effective agent
for severe hypertension outside pregnancy.47,48
Conclusion
Severe hypertension in pregnancy and postpartum should
be treated to decrease the risk of maternal stroke. Oral
agents would be particularly appropriate in the outpatient
setting while arranging transfer to hospital or in
resource-constrained institutions, such as busy delivery
suites in high-income settings or any maternity care
facility in low- and middle-income countries where the
vast majority of HDP-related maternal complications
occur.
The oral antihypertensive agent for which there is the
most evidence for treatment of severe hypertension in preg-
nancy/postpartum is nifedipine (10 mg). Labetalol
(100 mg) and methyldopa (250 mg) are reasonable sec-
ond-line options based on far more limited data. The
choice of an oral antihypertensive agent for a given woman
will be driven by many considerations, such as practitioner
familiarity, efficacy, low-risk of maternal hypotension,
duration of action, compatibility with magnesium sulphate,
and no important contraindications with regards to con-
comitant medical conditions.
Future trials should focus on head to head comparisons
of oral agents, particularly nifedipine, labetalol and methyl-
dopa; one such trial is underway (http://gynuity.org). Stud-
ies should also focus on early treatment of severe
hypertension in the community, particularly in low- and
middle-income countries where delays in triage and trans-
port could make antihypertensive treatment extremely
important for stroke prevention.
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